(KPL/Yonhap) Samsung Biologics Co. said Tuesday it has signed a deal worth US$1.24 billion for contract manufacturing from an Asia-based biopharmaceutical firm. The deal will last until the end of 2037, the company said in a regulatory filing. Other details remained undisclosed under a confidentiality agreement. Samsung Biologics said the deal reaches almost half of the value of its combined manufacturing deals for last year at 3.5 trillion won ($2.53 billion). So far this year, Samsung Biologics has secured nine deals worth a combined 4.36 trillion won with global biopharmaceutical companies. Source: Lao News Agency
Samsung Biologics wins US$1.24 bln deal for contract manufacturing
Recent News
Laos Clears Over 5,100 Hectares of Unexploded Ordnance in 2026
November 18, 2026
Vientiane Introduces Free Bus Services for That Luang Festival
November 18, 2026
Mobile Digital ID Registration Scheduled at Lao-ITECC in November
November 18, 2026
Laos Signs Agreement for 1,275 MW Wind Power Project in Savannakhet
November 18, 2026